CAH vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Cardinal Health presents a dichotomy of strong growth and fragile liquidity, anchored by a stable Piotroski F-Score of 4/9. While the company exhibits impressive YoY revenue and earnings growth (~19%) and consistently beats analyst estimates, its operational health is hampered by razor-thin profit margins (0.68%) and a concerning current ratio of 0.91. The stock is trading slightly below its intrinsic value of $205.03, but bearish insider activity and a 0/100 technical trend suggest immediate headwinds despite a 'strong_buy' analyst consensus.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
CAH vs MRK: Head-to-Head Comparison
This page compares Cardinal Health, Inc. (CAH) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.